MCRB · Seres Therapeutics Inc
United States · RS rating 2 · As of 2026-10-14
| Price | 2.42 USD |
|---|---|
| 1-day change | -4.3% |
| RS rating (overall / 1M / 3M / 12M) | 2 / 3 / 4 / 4 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 17 / 13 / 28 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +122.6% |
| Sales growth Q/Q | -54.6% |
| Distance from 52-week high | +91.5% |
| Market cap (USD) | $77.6M |